BE1030504B1 - COMPOSITE INSERT FOR THE TREATMENT OF DRY EYE - Google Patents
COMPOSITE INSERT FOR THE TREATMENT OF DRY EYEInfo
- Publication number
- BE1030504B1 BE1030504B1 BE20225347A BE202205347A BE1030504B1 BE 1030504 B1 BE1030504 B1 BE 1030504B1 BE 20225347 A BE20225347 A BE 20225347A BE 202205347 A BE202205347 A BE 202205347A BE 1030504 B1 BE1030504 B1 BE 1030504B1
- Authority
- BE
- Belgium
- Prior art keywords
- treatment
- dry eye
- composite insert
- mass
- cellulose derivative
- Prior art date
Links
- 208000003556 Dry Eye Syndromes Diseases 0.000 title 1
- 206010013774 Dry eye Diseases 0.000 title 1
- 239000002131 composite material Substances 0.000 title 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 abstract 3
- 229920002678 cellulose Polymers 0.000 abstract 3
- 239000001913 cellulose Substances 0.000 abstract 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 abstract 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 abstract 3
- 229920002385 Sodium hyaluronate Polymers 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 238000001125 extrusion Methods 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000465 moulding Methods 0.000 abstract 1
- 229940010747 sodium hyaluronate Drugs 0.000 abstract 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts, ocular implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Un insert ophthalmique biorésorbable comprenant au moins 25% en masse d’un premier dérivé de cellulose étant l’hydroxypropyle cellulose (HPC), ladite HPC ayant une masse moléculaire compris entre 800000 et 120000 Da, et entre 1 et 75% en masse d’un agent de viscosité constitué de l’hyaluronate de sodium, ou d’un second dérivé de cellulose différent de du premier dérivé de cellulose et procédés de fabrication par extrusion ou moulage.A bioresorbable ophthalmic insert comprising at least 25% by mass of a first cellulose derivative being hydroxypropyl cellulose (HPC), said HPC having a molecular mass of between 800,000 and 120,000 Da, and between 1 and 75% by mass of a viscosity agent consisting of sodium hyaluronate, or a second cellulose derivative different from the first cellulose derivative and manufacturing processes by extrusion or molding.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| BE20225347A BE1030504B1 (en) | 2022-05-06 | 2022-05-06 | COMPOSITE INSERT FOR THE TREATMENT OF DRY EYE |
| PCT/EP2023/061965 WO2023214027A1 (en) | 2022-05-06 | 2023-05-05 | Insert for the treatment of dry eyes |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| BE20225347A BE1030504B1 (en) | 2022-05-06 | 2022-05-06 | COMPOSITE INSERT FOR THE TREATMENT OF DRY EYE |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BE1030504A1 BE1030504A1 (en) | 2023-11-29 |
| BE1030504B1 true BE1030504B1 (en) | 2023-12-04 |
Family
ID=81748817
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BE20225347A BE1030504B1 (en) | 2022-05-06 | 2022-05-06 | COMPOSITE INSERT FOR THE TREATMENT OF DRY EYE |
Country Status (1)
| Country | Link |
|---|---|
| BE (1) | BE1030504B1 (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4343787A (en) * | 1975-07-29 | 1982-08-10 | Merck & Co., Inc. | Shaped ophthalmic inserts for treating dry eye syndrome |
| US4730013A (en) * | 1981-10-08 | 1988-03-08 | Merck & Co., Inc. | Biosoluble ocular insert |
| US20080193407A1 (en) * | 2007-02-09 | 2008-08-14 | Alcon, Inc. | Ophthalmic compositions containing a synergistic combination of three polymers |
| US20110129516A1 (en) * | 2009-10-30 | 2011-06-02 | Aton Pharma, Inc. | Ocular drug delivery devices |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3845201A (en) | 1972-04-24 | 1974-10-29 | S Loucas | Solid state ophthalmic medication delivery method |
| DK137946B (en) | 1973-12-17 | 1978-06-12 | Merck & Co Inc | Solid medium for use in ophthalmic preparations. |
| US6217896B1 (en) | 1999-04-01 | 2001-04-17 | Uab Research Foundation | Conjunctival inserts for topical delivery of medication or lubrication |
-
2022
- 2022-05-06 BE BE20225347A patent/BE1030504B1/en active IP Right Grant
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4343787A (en) * | 1975-07-29 | 1982-08-10 | Merck & Co., Inc. | Shaped ophthalmic inserts for treating dry eye syndrome |
| US4730013A (en) * | 1981-10-08 | 1988-03-08 | Merck & Co., Inc. | Biosoluble ocular insert |
| US20080193407A1 (en) * | 2007-02-09 | 2008-08-14 | Alcon, Inc. | Ophthalmic compositions containing a synergistic combination of three polymers |
| US20110129516A1 (en) * | 2009-10-30 | 2011-06-02 | Aton Pharma, Inc. | Ocular drug delivery devices |
Also Published As
| Publication number | Publication date |
|---|---|
| BE1030504A1 (en) | 2023-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sterner et al. | Reducing friction in the eye: a comparative study of lubrication by surface-anchored synthetic and natural ocular mucin analogues | |
| ATE273324T1 (en) | HEPARIN-LIKE SULPHATED POLYSACCHARIDES | |
| TW393498B (en) | The preparation and use of Polysiloxane-comprising perfluoroalkyl ethers | |
| AR049057A2 (en) | A QUICKLY REMOVABLE TABLET FOR ORAL ROUTE ADMINISTRATION | |
| BE1030504B1 (en) | COMPOSITE INSERT FOR THE TREATMENT OF DRY EYE | |
| JPH10508204A (en) | Polysaccharides with high iduronic acid content | |
| ES2082800T3 (en) | HYDROXIETILALMIDON AS A THINNER OF PLASMA AND ITS PREPARATION PROCEDURE. | |
| TW201636026A (en) | Ophthalmic agent and use of copolymers comprised therein | |
| CA2216919A1 (en) | Nanospheres comprising a biocompatible polysaccharide | |
| AlKhoury et al. | Study on the potential mechanism of anti‐inflammatory activity of covalently immobilized hyaluronan and heparin | |
| TWI798452B (en) | Contact lens product | |
| BR112022016415A2 (en) | MULTIPLE BASE CALLS TO ARTIFICIAL INTELLIGENCE BASED | |
| BR112022015380A2 (en) | COMPOSITIONS AND METHODS FOR EDITING KALLYKREIN GENE (KLKB1) | |
| CO5140079A1 (en) | PHARMACEUTICAL COMPOSITION OF SUSTAINED LIBERATION AND METHOD TO RELEASE A PHARMACEUTICALLY ACTIVE AGENT FROM SUSTAINED LIBERATION AND METHOD TO RELEASE A PHARMACEUTICALLY ACTIVE AGENT | |
| US20040127461A1 (en) | Water soluble, randomly substituted partial N-, partial O-acetylated chitosan, preserving compositions containing chitosan, and processes for making thereof | |
| WO2023235838A3 (en) | Rna-targeting splicing modifiers for treatment of foxp3-associated conditions and diseases | |
| HUP9903666A2 (en) | A process for preparing a hyaluronic acid fraction having a low polydispersion index | |
| FI972527A0 (en) | coating System | |
| TW201900786A (en) | Solution for silicone hydrogel contact lens and distribution solution including the same improving the surface hydrophilicity and surface lubricity of a silicone hydrogel contact lens | |
| DE69527081D1 (en) | MULTIPLE UNSATURATED CARBOHYDRATE DERIVATIVES, POLYMERS THEREOF AND THEIR USE | |
| Khangtragool et al. | Chitosan as an ocular drug delivery vehicle for vancomycin | |
| BE1030503B1 (en) | INSERT FOR THE TREATMENT OF DRY EYE | |
| AR004360A1 (en) | PHARMACEUTICAL COMPOSITIONS FOR THE THERAPY OF CARCINOMAS OF THE FLAT EPITHELIUM AND AN AGENT TO BE EMPLOYED IN THESE PHARMACEUTICAL COMPOSITIONS. | |
| WO2022010939A3 (en) | Peptides and methods of using the same | |
| JP4290231B2 (en) | Corneal disorder healing promoter |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Patent granted |
Effective date: 20231204 |